ASH Clinical News Hematology Pipeline Update | Page 11

THE FIRST AND ONLY rFVIII WITH A PROLONGED HALF-LIFE

57%

OF HTCs HAVE
PRESCRIBED
ELOCTATE†
*

Find out more at
ELOCTATEpro.com

*79 of 137 hemophilia treatment centers (HTCs).
†
Based on US distribution data for ELOCTATE 7/14/2014-11/12/2014.

INDICATIONS: ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is a recombinant DNA
derived, antihemophilic factor indicated in adults and children with Hemophilia A (congenital Factor VIII
deficiency) for: control and prevention of bleeding episodes, perioperative management (surgical prophylaxis),
and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ELOCTATE is not indicated
for the treatment of von Willebrand disease.
Selected Important Safety Information
• ELOCTATE is contraindicated in patients who have had life-threatening hypersensitivity reactions to
ELOCTATE, including anaphylaxis

Please see Brief Summary of full Prescribing Information on the following pages.
This information is not intended to replace discussions with your healthcare provider.

© 2015 Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142. All rights reserved. ELO-US-0161 02/15